What are the latest femtech trends?

This blog post has been written by the person who has mapped the femtech market in a clean and beautiful presentation

FemTech has evolved from basic period-tracking apps into a sophisticated ecosystem worth $62.7 billion, spanning reproductive health, menopause support, and AI-driven diagnostics.

While legacy solutions like fertility monitoring remain strong, emerging trends like quantum-enhanced diagnostics and hormonal wellness platforms are reshaping the landscape. Investors should look beyond traditional segments into underserved areas like menopause tech and cardiovascular women's health for the highest growth potential through 2026.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Get a Clear, Visual
Overview of This Market

We've already structured this market in a clean, concise, and up-to-date presentation. If you don't have time to waste digging around, download it now.

DOWNLOAD THE DECK

What femtech trends have been around for a long time and remain relevant today?

Four foundational femtech categories continue to drive user adoption and investment despite being over a decade old.

Period-tracking apps like Clue and Flo Health maintain millions of active users because they solve a universal need for cycle prediction and symptom logging. These platforms have evolved beyond basic calendars to include educational content, community features, and integration with wearables.

Fertility monitoring and family planning solutions sustain strong demand through wearables and at-home hormone tests. Companies like Kindbody and Maven Clinic have expanded from simple ovulation tracking to comprehensive reproductive health platforms offering telehealth consultations, sperm analysis, and IVF support.

Telehealth and virtual care for women's health continue expanding access to OB/GYN services, contraception counseling, and postnatal support. The COVID-19 pandemic accelerated adoption, and these services now serve underserved populations in rural areas and countries with limited healthcare infrastructure.

Contraceptive technologies, particularly smart devices like digital diaphragms and hormone-free methods, retain significant market share as women seek alternatives to traditional hormonal birth control. These solutions address growing concerns about side effects and long-term health impacts of hormonal contraceptives.

Which femtech trends are completely new and emerging right now?

Four cutting-edge trends are reshaping femtech with technologies that didn't exist in the consumer health space five years ago.

AI-powered personalization platforms use machine learning to tailor nutrition, fitness, and mental health recommendations across different menstrual cycle phases. These systems analyze thousands of data points to create adaptive wellness plans that adjust based on hormonal fluctuations and individual responses.

Quantum-enhanced diagnostics represent the frontier of biomarker discovery, with early research suggesting quantum computing can accelerate identification of PCOS and endometriosis markers by processing complex molecular data patterns impossible for traditional computers to analyze efficiently.

Hormonal wellness platforms combine AI-driven hormone tracking with non-invasive wearable sensors for dynamic cycle mapping. These solutions monitor cortisol, estrogen, and progesterone levels through skin patches and breath analysis, providing real-time insights without blood draws.

Digital therapeutics (DTx) apps are entering clinical trials as prescription treatments for endometriosis pain and menopausal symptoms. Unlike wellness apps, these solutions require FDA approval and demonstrate measurable clinical outcomes equivalent to traditional pharmaceuticals.

If you want updated data about this market, you can download our latest market pitch deck here

Which femtech trends were once popular but have lost momentum?

Three previously hyped categories have plateaued or declined due to limited clinical validation or market saturation.

Cycle-syncing services that promised to optimize workouts and nutrition based on menstrual phases have lost momentum after studies failed to demonstrate significant performance benefits. The concept became more of a marketing trend than a scientifically validated approach to wellness.

Basic wearable patches without clinical validation struggled to gain adoption after initial launches. Many early-stage companies promised advanced sensing capabilities but couldn't deliver accurate results or obtain regulatory approval for health claims.

Single-purpose fertility apps focused solely on ovulation calculations have seen declining usage as users migrate to comprehensive platforms. Modern users expect integrated solutions that combine cycle tracking with telehealth, community features, and personalized insights rather than standalone calculators.

The Market Pitch
Without the Noise

We have prepared a clean, beautiful and structured summary of this market, ideal if you want to get smart fast, or present it clearly.

DOWNLOAD

What femtech trends seem to be more hype than substance?

Several high-visibility trends lack clinical evidence or market validation despite significant media attention and investment.

Menstrual "smart" underwear has generated numerous product launches claiming advanced sensing capabilities, but few companies have published peer-reviewed efficacy studies. Most products rely on basic moisture detection rather than sophisticated biomarker analysis, making their health claims questionable.

CBD-infused tampons and menstrual products have received celebrity endorsements and media coverage, but clinical evidence for symptom relief remains scant. The FDA has not approved any CBD menstrual products for therapeutic claims, and many products contain insufficient active compounds to provide measurable benefits.

Blockchain cycle data platforms promised enhanced security and data ownership for menstrual tracking information. However, limited user adoption demonstrates that the complexity and technical requirements outweigh the perceived benefits of decentralized data storage for most consumers.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

Which femtech trends are currently gaining real traction and momentum?

Three categories show validated clinical outcomes, strong user retention, and documented revenue growth that indicate sustainable market traction.

Menopause care platforms combining virtual clinics with wearable cooling devices report 85%+ user retention rates and clinical endorsements from major medical associations. Companies like Bastet Rising and MyMenopauseRx have demonstrated measurable improvements in symptom management and quality of life metrics.

Integrative mental health apps combining cognitive behavioral therapy (CBT), hypnotherapy, and peer support for perinatal and premenopausal users are scaling rapidly. These platforms show clinical validation through reduced anxiety and depression scores, with some achieving prescription status through healthcare providers.

Hormone-profiling services using at-home testing kits for PCOS, thyroid issues, and personalized therapy guidance have achieved profitability and clinical partnerships. Companies like Hertility Health and Level Zero Health process thousands of tests monthly and provide actionable treatment recommendations validated by medical professionals.

Which startups and key players are working on each specific femtech trend?

Trend Category	Key Players & Startups	Notable Differentiators
Period & Menstrual Health	Clue (15M+ users), Flo Health (240M+ users), HeraMED (clinical focus)	Integration with wearables, educational content, clinical partnerships
Fertility & Family Planning	Kindbody (clinic network), Maven Clinic (B2B focus), Future Family (financing), Béa Fertility (device), Woom Fertility (AI coaching)	End-to-end services, employer benefits, financing options
Menopause Support	Bastet Rising (AI advocate), Amira (community platform), MyMenopauseRx (prescription), Willow (device pivot)	Clinical validation, personalized treatment, wearable integration
Mental Wellness Integration	Wysa (AI chatbot), Seven Starling (perinatal), Clementine (teen focus), Happy Thing (mood tracking)	Specialized populations, clinical integration, evidence-based interventions
Diagnostics & Hormone AI	Hertility Health (fertility testing), Level Zero Health (hormone optimization), OvuSense (continuous monitoring), Epicore (biomarkers)	Proprietary testing methods, AI analysis, clinical partnerships
Digital Therapeutics	Ginger.io (behavioral coaching), Elvie (pelvic floor), Madorra (device-based therapy)	FDA pathway, clinical trials, prescription status
Cardiovascular Women's Health	Emerging market with limited dedicated players	Major opportunity for new entrants with clinical focus

If you want to grasp this market fast, you can download our latest market pitch deck here

What are the main problems these femtech solutions are trying to solve?

Femtech addresses four critical healthcare gaps that disproportionately affect women and cost the economy billions annually.

Diagnostic delays for conditions like endometriosis and PCOS average 7-10 years, during which women experience pain, reduced quality of life, and fertility complications. Current medical training and diagnostic tools often miss or misinterpret women-specific symptoms, leading to misdiagnosis and inappropriate treatments.

Access barriers and stigma prevent women from seeking care for taboo topics including menopause, sexual health, and mental wellness. Traditional healthcare systems often lack specialized knowledge about women's hormonal health, and cultural stigmas discourage open discussion of symptoms and treatment options.

Personalization gaps in treatment approaches fail to account for individual hormonal variations and life stages. Most medical research historically focused on male subjects, resulting in one-size-fits-all treatments that don't optimize for women's cyclical hormone patterns and unique physiological responses.

Workplace productivity losses from menopausal and menstrual symptoms cost employers an estimated $150 billion annually in the US alone. These conditions affect concentration, attendance, and performance, yet most workplace health benefits don't address women's life-stage specific needs or provide adequate support systems.

We've Already Mapped This Market

From key figures to models and players, everything's already in one structured and beautiful deck, ready to download.

DOWNLOAD

How large is the current market opportunity for each femtech trend?

The global femtech market reached $62.7 billion in 2024 and is projected to grow at 13.1% CAGR to $310.7 billion by 2037, with digital health solutions capturing over 50% market share.

Market Segment	2024 Value	2025-2028 Growth	Key Growth Drivers
Overall FemTech Market	$62.7 billion	13.1% CAGR to $310.7B by 2037	Digital transformation, aging population, workplace wellness
Software & Digital Health	~$31.7 billion (50.7%)	Fastest growing segment	AI integration, telehealth adoption, subscription models
Fertility & Reproductive	~$18.8 billion (30%)	Sustained growth via at-home testing	Delayed childbearing, IVF accessibility, male fertility focus
Menopause Solutions	~$4.4 billion (7%)	Growing to 15%+ by 2028	Baby boomer demographics, workplace initiatives, clinical validation
Mental Health Integration	~$6.3 billion (10%)	20%+ annual growth	Perinatal depression awareness, employer benefits, clinical integration
Hormone Diagnostics	~$5.0 billion (8%)	15-18% CAGR	At-home testing adoption, AI analysis, personalized medicine
Cardiovascular Women's Health	Minimal current market	Untapped potential	75M years of healthy life lost annually, few dedicated solutions

What unmet needs still exist in femtech that could attract investment or innovation?

Four major white space opportunities represent billions in potential market value for entrepreneurs and investors willing to tackle complex, underserved problems.

Cardiovascular women's health represents the largest unmet need, with over 75 million years of healthy life lost annually to heart disease in women. Few femtech companies target female-specific cardiovascular risk factors like pregnancy complications, hormonal transitions, and autoimmune conditions that increase heart disease risk differently than in men.

Integrative longevity and preventative care for women beyond reproductive years lacks comprehensive solutions. The market focuses heavily on fertility and pregnancy, leaving a gap for perimenopause and post-menopause health monitoring, bone density management, and age-related hormone optimization.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

Menopause education and employer solutions represent an emerging B2B opportunity as companies recognize productivity losses from menopausal symptoms. Corporate benefits platforms certified for women's life-stage wellness could capture significant enterprise value while improving workplace outcomes.

Digital biomarkers for rare women's health conditions including endometriosis, uterine fibroids, and pelvic floor disorders lack adequate diagnostic tools. These conditions affect millions of women but receive limited research funding and have few dedicated technology solutions for early detection and management.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

What can be expected in the femtech industry landscape by 2026?

Four major shifts will reshape the femtech landscape by 2026, creating consolidation opportunities and new regulatory pathways for investors and entrepreneurs.

Market consolidation through mergers and acquisitions will accelerate as fertility and menopause apps seek scale to compete with larger healthcare platforms. Companies with strong user bases but limited monetization will become acquisition targets for established health tech firms seeking to expand into women's health.

Regulatory clarity from FDA approvals for digital therapeutics in women's health will legitimize the sector and enable prescription-based revenue models. The first wave of DTx approvals for endometriosis and menopause management will create precedents for clinical validation requirements and reimbursement pathways.

Employer-led femtech benefits integration will become standard in competitive talent markets, with B2B platforms integrated into health plans and wellness programs. Companies will offer comprehensive women's health benefits including menopause support, fertility coverage, and mental health resources as recruitment and retention tools.

Advanced AI and quantum research applications will enter clinical trials, leveraging quantum-accelerated biomarker discovery for personalized hormone therapies and precision medicine approaches to women's health conditions previously treated with generic protocols.

How is the femtech market expected to evolve over the next five years?

The femtech market will transform from a niche wellness category into a mainstream healthcare sector with validated clinical outcomes and integrated healthcare delivery models.

Platform consolidation will create comprehensive women's health ecosystems that combine multiple services under single platforms. Instead of separate apps for periods, fertility, and menopause, integrated platforms will provide lifecycle health management from adolescence through post-menopause with AI-driven personalization.

Clinical integration with traditional healthcare systems will accelerate as femtech companies partner with hospitals, insurance providers, and pharmaceutical companies. These partnerships will enable data sharing, prescription capabilities, and reimbursement models that legitimize femtech as medical devices rather than consumer wellness products.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

Global expansion will drive growth as femtech companies adapt products for international markets with different regulatory environments, cultural attitudes, and healthcare systems. Emerging markets represent significant opportunities for mobile-first solutions that can provide women's health services in regions with limited healthcare infrastructure.

AI-driven personalization will become the standard expectation, with solutions that adapt in real-time to individual hormonal patterns, lifestyle factors, and treatment responses. Generic one-size-fits-all approaches will become obsolete as consumers expect personalized recommendations validated by their own health data.

We've Already Mapped This Market

From key figures to models and players, everything's already in one structured and beautiful deck, ready to download.

DOWNLOAD

Where are the most promising opportunities for new entrants or investors to make an impact in femtech today?

Four specific investment corridors offer the highest potential returns and market impact for entrepreneurs and investors entering femtech in 2025.

Menopause technology represents the most undervalued opportunity, with a market growing from 7% to 15%+ of femtech spending by 2028. Wearable cooling devices, AI-powered symptom tracking, and clinical-grade supplements backed by peer-reviewed research can capture significant market share in this underserved demographic with high disposable income.

Hormonal wellness platforms using AI-trained models for adaptive hormone therapy optimization offer first-mover advantages in personalized medicine. These solutions can command premium pricing by demonstrating measurable health outcomes and reducing trial-and-error approaches to hormone replacement therapy and cycle management.

Mental health integrations specifically designed for women's hormonal fluctuations during perinatal, perimenopausal, and post-menopausal periods represent a clinical need with validated market demand. Solutions combining CBT, peer support, and hormonal health education can achieve both clinical validation and sustainable revenue models.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

Non-invasive diagnostics using lab-on-a-chip technology for ovarian reserve testing and endometriosis screening can disrupt traditional diagnostic pathways. These solutions address the 7-10 year diagnostic delay problem while creating recurring revenue through test kit subscriptions and clinical partnerships.

Conclusion

Sources

1. MHA - FemTech: The Rapid Growth of Women's Health Innovation
2. Tech Funding News - Next Gen Fertility Startups
3. Forbes - Innovations in Fertility FemTech Companies
4. Health IT Answers - The Future of FemTech 7 Trends
5. Phase App - FemTech Trends We're Watching in 2025
6. Global Wellness Institute - Hormonal Wellness Initiative Trends
7. Galen Growth - FemTech's Rise and Roadblocks
8. Sifted - 30 FemTech Startups to Watch
9. FemTech Canada - Bastet Rising Personal Advocate
10. FemTech Insider - 51 Labs Cohort Menopause
11. Startups Magazine - FemTech Mental Health Empowerment
12. FemTech World - Mental Health Startups Awards
13. FemTech Insider - Mental Health Category
14. FemTech Insider - What's New in FemTech February 2025
15. Research Nester - FemTech Market Report
16. PreScouter - Untapped Menopause Market Opportunity
17. Fenwick - NY Tech Week The Future of FemTech